NCT02216578 is a Phase 2 clinical trial of cabozantinib in Metastatic Gastrointestinal Stromal Tumor, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

Who is sponsoring NCT02216578?

NCT02216578 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

What drugs are being tested in NCT02216578?

Interventions in NCT02216578: cabozantinib.

What condition does NCT02216578 study?

NCT02216578 studies Metastatic Gastrointestinal Stromal Tumor.

Is NCT02216578 still recruiting?

NCT02216578 is currently completed. Last updated 15 July 2021.

Last reviewed 2021-07-15 · How we verify

NCT02216578

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ph II CABOGIST in GIST

Completed Phase 2 Last updated 15 July 2021

What this trial tests

Phase 2 trial testing cabozantinib in Metastatic Gastrointestinal Stromal Tumor in 51 participants. Completed in 23 February 2021.

Timeline

2 February 2017

Primary endpoint
20 May 2019

23 February 2021

Quick facts

Lead sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	51
Start date	2 February 2017
Primary completion	20 May 2019
Estimated completion	23 February 2021
Sites	11 locations across France, Belgium, United Kingdom, Germany, Hungary, Czechia

Drugs / interventions tested

cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

Metastatic Gastrointestinal Stromal Tumor — all drugs for Metastatic Gastrointestinal Stromal Tumor →

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC — full company profile →

Who can join

18 and older, any sex, with Metastatic Gastrointestinal Stromal Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a multi-center, multi-national, open label, single arm Phase II study of single-agent cabozantinib. The objective of the study is to assess the safety and activity of cabozantinib in patients with metastatic GIST who have previously progressed on imatinib and sunitinib and have not been exposed yet to other KIT- or PDGFR-directed tyrosine kinase inhibitors. Patient will receive cabozantinib until they experience no further benefit from the treatment, becoming intolerant to the drug or wishing to discontinue the treatment. Treatment beyond RECIST 1.1 progression is allowed in patients deriving clinical benefit upon investigator's discretion, provided no other criteria for treatment withdrawal are met.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.
Yang Y, Li S, Wang Y, Zhao Y, et al · · 2022 · cited 182× · PMID 36115852 · DOI 10.1038/s41392-022-01168-8
BDNF and its signaling in cancer.
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, et al · · 2023 · cited 48× · PMID 36173463 · DOI 10.1007/s00432-022-04365-8
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
Schöffski P, Mir O, Kasper B, Papai Z, et al · · 2020 · cited 47× · PMID 32470848 · DOI 10.1016/j.ejca.2020.04.021
Advances and Challenges on Management of Gastrointestinal Stromal Tumors.
Mei L, Du W, Idowu M, von Mehren M, et al · · 2018 · cited 35× · PMID 29868467 · DOI 10.3389/fonc.2018.00135
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Bauer S, Joensuu H. · · 2015 · cited 27× · PMID 26187774 · DOI 10.1007/s40265-015-0440-8
New frontiers in the medical management of gastrointestinal stromal tumours.
Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, et al · · 2019 · cited 26× · PMID 31205499 · DOI 10.1177/1758835919841946
The treatment landscape in thyroid cancer: a focus on cabozantinib.
Weitzman SP, Cabanillas ME. · · 2015 · cited 24× · PMID 26316818 · DOI 10.2147/cmar.s68373
Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors.
Dufresne A, Pissaloux D, Ngo C, Penel N, et al · · 2023 · cited 11× · PMID 37054503 · DOI 10.1016/j.esmoop.2023.101202

Verify or expand the search:

Other trials of cabozantinib

Trials testing the same drug.

NCT04151563 — A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After F · Phase 1, PHASE2 · withdrawn
NCT03729245 — A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of · Phase 3 · terminated
NCT03354884 — caBozantinib in cOllectiNg ductS Renal Cell cArcInoma · Phase 2 · completed
NCT03170960 — Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tu · Phase 1 · active not recruiting

Other recruiting trials for Metastatic Gastrointestinal Stromal Tumor

Currently open trials in the same condition.

NCT04595747 — Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast · Phase 2 · active not recruiting

Other European Organisation for Research and Treatment of Cancer - EORTC trials

Trials by the same sponsor.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT06978062 — Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment · Phase 1 · not yet recruiting
NCT06809322 — Vorasidenib Maintenance for IDH Mutant Astrocytoma · Phase 3 · recruiting
NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06783348 — Radiopharmaceutical Treatment of Advanced Kidney Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02216578 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Organisation for Research and Treatment of Cancer - EORTC
Last refreshed: 15 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02216578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing